Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Anileridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 9/20 | 0.68 |
| ▸ | OPRK1 known ✓ | P41145 | 6/20 | 0.68 |
| ▸ | KCNA3 | P22001 | 3/20 | 0.74 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.68 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anileridine SCHEMBL27722317 | 1.00 | KCNA3 (0.74) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Anileridine SCHEMBL119086 | 0.99 | KCNA3 (0.72) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Anileridine SCHEMBL7119028 | 0.99 | KCNA3 (0.72) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Anileridine SCHEMBL1237724 | 0.96 | KCNA3 (0.69) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Pheneridine SCHEMBL1922392 | 0.92 | KCNA3 (0.86) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Anileridine SCHEMBL8741179 | 0.91 | KCNA3 (0.66) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Phenoperidine SCHEMBL28832646 | 0.91 | KCNA3 (0.67) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL7313939 | 0.85 | KCNA3 (1.00) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11712840 | 0.83 | OPRM1 (0.82) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11601769 | 0.82 | OPRM1 (0.80) | KCNA3OPRM1OPRD1OPRK1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11691 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CELLIS AG (CH) | 2026-04-02 | — | — | US | claimed |
| EP-4659014-A1 | EMULSION-BASED THICK-FILM ANTIFOULING COATING FOR HIGHLY SENSITIVE ELECTROCHEMICAL SENSING | President And Fellows Of Harvard College (US) | 2025-12-10 | — | — | EP | claimed |
| EP-4637829-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF OVARIAN CANCER | Cellis Sp. z o.o. ([Ltd.] (PL) | 2025-10-29 | — | — | EP | claimed |
| US-20250319074-A1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2025-10-16 | — | — | US | claimed |
| US-12440489-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-10-14 | — | — | US | claimed |
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| EP-4594520-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2025-08-06 | — | — | EP | claimed |
| EP-4587062-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | Cellis AG (CH) | 2025-07-23 | — | — | EP | claimed |
| US-20250228771-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-07-17 | — | — | US | claimed |
| US-5321012-A | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL COLLEGE (US) | 1994-06-14 | — | — | US | claimed |
| WO-1993007892-A1 | COMPOSITION AND TREATMENT WITH BIOLOGICALLY ACTIVE PEPTIDES AND ANTIBIOTIC | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 1993-04-29 | — | — | WO | claimed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | claimed |
| US-4725355-A | SULFA DRUG ON SUPPORT | TERUMO KABUSHIKI KAISHA (JP) | 1988-02-16 | — | — | US | claimed |
| EP-0222425-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-05-20 | — | — | EP | claimed |
| EP-0218300-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-04-15 | — | — | EP | claimed |
| EP-0068838-B1 | ANALGESIC PROCESS AND COMPOSITION | THE UPJOHN COMPANY (US) | 1986-09-17 | — | — | EP | claimed |
| US-4489080-A | SYNERGISTIC COMBINATION OF NARCOTIC AND FLURBIPROFEN OR ESTER | THE UPJOHN COMPANY (US) | 1984-12-18 | — | — | US | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |
| US-4022703-A | Stabilization of hydrogen peroxide in acid baths for cleaning metals | PRODUITS CHIMIQUES UGINE KUHLMANN (FR) | 1977-05-10 | — | — | US | claimed |